Impella 5.0作为体外生命支持后神经预后不明患者的决策桥接治疗
本研究回顾性分析22例神经状态不明的体外生命支持(ECLS)患者,均接受Impella 5.0植入。所有患者成功脱离ECLS,30天生存率68.2%,约三分之二患者存活且神经功能可接受,Impella 5.0为决策桥接提供可行选择。
要点
- Impella 5.0可为ECLS后神经预后不明患者提供决策桥接。
- 所有患者经腋动脉植入Impella 5.0后成功脱离ECLS。
- 30天生存率68.2%,存活者神经功能定量指标改善。
核心结论
- Impella 5.0支持为ECLS植入后患者提供决策桥接选择并实现左心室卸载。
- 该策略允许进一步评估神经状态并促进后续治疗,约三分之二患者存活且神经结局可接受。
研究设计与样本
- 回顾性研究,纳入2016年1月至2018年7月单中心22例ECLS后神经状态不明并接受Impella 5.0植入的患者。
- 平均年龄56.5±10.7岁,每日采用脑功能分类评分和改良Rankin量表评估神经状态。
主要发现
- 16例(72.7%)在ECLS植入前接受复苏,13例(59.1%)为急性心肌梗死。
- Impella 5.0植入前ECLS平均持续9.3±1.7天,Impella 5.0平均支持16.3±4.7天。
- 所有患者通过腋动脉植入Impella 5.0后成功脱离ECLS。
- 存活者30天后脑功能定量测量较基线改善(P < 0.01)。
- 6例(27.3%)桥接至持久性左心室辅助装置,9例(40.9%)心肌功能恢复并成功撤除Impella 5.0,30天生存率68.2%。
临床怎么用
- 对ECLS后无法脱机且神经预后不明的患者,可考虑Impella 5.0作为决策桥接以争取神经评估时间。
- Impella 5.0支持期间需每日评估神经状态,根据恢复情况决定桥接至持久设备、撤除或其它治疗。
局限性
- 回顾性单中心研究,样本量小(22例),缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Peripheral venoarterial extracorporeal life support (ECLS) for the treatment of cardiogenic shock has shown to improve survival but is associated with complications. However, if the patient cannot be weaned from ECLS, their therapy options are limited. Although durable left ventricular assist device implantation might be an option in such cases, an unclear neurological outcome is often a contraindication. We hypothesize that Impella 5.0 therapy provides sufficient circulatory support while avoiding ECLS-related complications, thereby allowing for an adequate evaluation of a patient's neurological state and facilitating further treatment options. METHODS: We retrospectively reviewed data from 22 ECLS patients (mean age 56.5 ± 10.7 years) with an unclear neurological status who underwent Impella 5.0 implantation between January 2016 and July 2018 in our institution. Neurological status was evaluated on a daily basis using the cerebral performance category score and the modified Rankin scale. RESULTS: Sixteen patients (72.7%) were resuscitated before ECLS implantation and 13 patients (59.1%) had acute myocardial infarction. The mean duration on ECLS before Impella 5.0 implantation was 9.3 ± 1.7 days. All patients were successfully weaned from ECLS by Impella 5.0 implantation via the axillary artery. The mean duration on Impella 5.0 was 16.3 ± 4.7 days. In surviving patients, both quantitative measurements of cerebral performance improved after 30 days compared to the baseline (P < 0.01). Six patients (27.3%) were bridged to a durable left ventricular assist device. In 9 patients (40.9%), myocardial function recovered during Impella 5.0 support and the device was successfully explanted. The 30-day survival rate was 68.2%. CONCLUSIONS: Impella 5.0 support provides a bridge-to-decision option for patients following ECLS implantation and leads to left ventricular unloading. It allows further evaluation of a patient's neurological situation and facilitates further therapy. About two-thirds of patients survived with acceptable neurological outcomes.
引用
- Bernhardt AM, Zipfel S, Reiter B, et al. Impella 5.0 therapy as a bridge-to-decision option for patients on extracorporeal life support with unclear neurological outcomes. Eur J Cardiothorac Surg. 2019. PMID: 31038672. doi:10.1093/ejcts/ezz118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。